What is the recommended treatment and infection control strategy for Clostridioides difficile infection in a skilled nursing facility?

Treatment of Clostridioides difficile Infection in Skilled Nursing Facilities

For initial CDI episodes in SNF residents, use fidaxomicin 200 mg twice daily for 10 days as first-line therapy, or vancomycin 125 mg four times daily for 10 days as an acceptable alternative; metronidazole should only be used for nonsevere CDI when preferred agents are unavailable. 1

Treatment Algorithm by Clinical Presentation

Initial CDI Episode

• Preferred: Fidaxomicin 200 mg orally twice daily for 10 days 1
• Alternative: Vancomycin 125 mg orally four times daily for 10 days 1
• Last resort (nonsevere CDI only): Metronidazole 500 mg three times daily for 10-14 days, but only if WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL 1

The IDSA/SHEA 2021 guidelines explicitly prioritize fidaxomicin over vancomycin, though implementation depends on available resources—a critical consideration in SNF settings where formulary restrictions may apply. 1

First Recurrence

• Preferred: Fidaxomicin 200 mg twice daily for 10 days, OR extended regimen (twice daily for 5 days, then every other day for 20 days) 1
• Alternative: Vancomycin in tapered/pulsed regimen (125 mg four times daily for 10-14 days, then twice daily for 7 days, once daily for 7 days, then every 2-3 days for 2-8 weeks) 1
• Adjunctive therapy: Consider bezlotoxumab 10 mg/kg IV once during antibiotic treatment, particularly for residents >65 years, immunocompromised patients, or those with severe CDI—but use caution in congestive heart failure 1

Multiple Recurrences (≥2 recurrences)

• Continue fidaxomicin or tapered vancomycin regimens 1
• Alternative combination: Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days 1
• Fecal microbiota transplantation: Only after failure of at least 2 recurrences (meaning 3 total CDI episodes), with appropriate donor screening per FDA safety alerts regarding pathogenic E. coli and SARS-CoV-2 transmission 1

Fulminant CDI

• Vancomycin 500 mg four times daily orally or via nasogastric tube 1
• Add rectal vancomycin instillation if ileus present 1
• Plus IV metronidazole 500 mg every 8 hours in combination with oral/rectal vancomycin, especially with ileus 1
• Fulminant CDI indicators: hypotension/shock, ileus, or megacolon 1

Infection Control Strategies for SNF Settings

Diagnostic Approach

• Submit a single diarrheal stool specimen for C. difficile toxin assay in residents with colitis symptoms (fever, abdominal cramps, diarrhea ± blood/WBCs), especially with antibiotic exposure in prior 30 days 1
• If diarrhea persists with negative initial test, submit 1-2 additional specimens 1
• Many SNFs lack protocols to identify CDI—only 42.2% of Iowa facilities had identification protocols, and 77.5% only tested with severe diarrhea 2

Isolation and Contact Precautions

• Place residents in private rooms when possible (though only 58.5% of surveyed SNFs consistently did this) 2
• Implement contact precautions with gown and gloves 3
• Critical pitfall: Maintaining prolonged contact precautions in SNFs is challenging; facilities found it difficult to sustain precautions for 30 days post-resolution 3
• Cohorting CDI-positive residents together is practiced by 60.9% of facilities, though this requires careful consideration of resident quality of life 2

Hand Hygiene

• Use soap and water, not alcohol-based hand sanitizers, as alcohol does not kill C. difficile spores 3
• Common pitfall: 71.5% of surveyed SNFs allowed staff to use alcohol-based gel after contact with CDI residents, which is inadequate 2
• Hand hygiene compliance remained poor (approximately 52%) even with reinforcement efforts 3

Environmental Management

• Use EPA-registered sporicidal disinfectants (bleach-based products) for environmental cleaning 3
• Clean high-touch surfaces and equipment in resident rooms daily 3
• Environmental contamination with C. difficile was rarely detected when proper cleaning protocols were followed 3

Antimicrobial Stewardship in SNFs

Implement antibiotic stewardship programs to reduce CDI risk, as only 25.1% of surveyed SNFs had such programs despite antibiotics being the primary CDI risk factor. 2

• Standardized probiotic protocols during antibiotic courses showed significant CDI reduction (from 5.8 to 0.3 cases per 10,000 patient-days) with net annual savings of $72,544-$154,085 in one SNF study 4
• However, bundled interventions in SNFs are challenging with limited resources and may be more successful with fewer components and intensive execution 3
• Antibiotic exposure remains the major modifiable risk factor alongside C. difficile exposure 5

Special Considerations for SNF Residents

• SNF residents have multiple comorbidities and frequent antibiotic exposures, making them highly vulnerable to CDI 4
• Age >65 years is an independent risk factor for recurrence, making bezlotoxumab particularly relevant in this population 1
• Most SNFs (94.3%) accept residents with known CDI, but many infections remain undiagnosed due to inadequate testing protocols 2
• Proton pump inhibitor use significantly increases CDI risk and should be minimized when possible 6